ISFIYA, Israel, March 31, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the fourth quarter and full year ended December 31, 2022.

2022 and Recent Highlights:

• In March 2023, the Company announced that following the Company's internal assessment of the clinical data collected to date from its calibration studies, the Company has determined that the current efficacy results do not meet its goal to proceed to the powered portion of the U.S. pivotal study. As a result, the Company has adopted a plan of actions that includes conducting additional clinical data analysis and approaching the U.S. Food and Drug Administration ("FDA") to make amendments to the U.S. pivotal study protocol that are expected to be part of an IDE supplement submission to the FDA, and which are subject to FDA approval. In addition, the Company plans to continue conducting its calibration studies, albeit at a slower pace, to collect additional clinical data and the Company is also implementing a cost reduction plan in order to extend its cash runway for a longer period than initially planned. The initiation of the powered portion of the U.S. pivotal study that was expected in mid-2023 is therefore temporarily postponed.
• In March 2022, the Company consummated a $10 million registered direct offering. Based on the abovementioned plan, the Company believes that current cash on hand will be sufficient to fund its ongoing operations and plans into the fourth quarter of 2024.
• Intellectual Property: During the year 2022, the Company was granted two new patents: 
  • "Position Estimation of Imaging Capsule in Gastrointestinal Tract" granted in Israel, covering C-Scan's proprietary tracking technology, which enables real time tracking of the capsule and its activation when it moves throughout the colon. This functionality allows for optimal scanning along the gastrointestinal (GI) tract while maintaining low energy consumption during the procedure. The patent also covers the capsule positioning data recording utilized by the C-Scan analysis suite, which enables gastroenterologists to make a clinical decision and generate a report with their diagnosis and recommendations. Corresponding patents were granted in Japan, China, Europe and the United States.
  • "System and method for polyp detection through capsule dynamics" granted in Japan. This patent was submitted following analysis of hundreds of patients that showed that certain capsule dynamic properties correlate with increased likelihood for the presence of polyps. Corresponding patents were filed in Europe and the United States.

"Our current primary focus is to continue collecting additional clinical data, while analyzing the data collected thus far. In parallel, we intend to leverage our Breakthrough Designation and engage with the FDA with the aim to obtain feedback and determine next steps with respect to the powered portion of the U.S. pivotal trial," said Alex Ovadia, chief executive officer of Check-Cap.

Financial Results for the Fourth Quarter Ended December 31, 2022

Research and development expenses, net, were $3.0 million for the three months ended December 31, 2022 compared to $4.1 million for the same period in 2021.  The decrease is primarily due to (i) a $0.6 million reduction in salary and related expenses, mainly as a result of a reduction in bonuses expense in 2022 and currency exchange rate fluctuation, and (ii) a decrease of approximately $0.6 million in material expenses.

General and administrative expenses were $1.3 million for the three months ended December 31, 2022, compared to $1.5 million for the same period in 2021. The decrease is primarily due to a $0.3 million decrease in salary and related expenses, mainly as a result of a reduction in bonuses expense in 2022, offset in part by an increase of $0.1 million in other general and administrative expenses.

Operating loss was $4.2 million for the three months ended December 31, 2022, compared to an operating loss of $5.6 million for the same period in 2021.

Finance income, net, was approximately $502,000 for the three months ended December 31, 2022, compared to $101,000 for the same period in 2021. The change in finance income, net is primarily due to an increase of $470,000 of interest income on short-term deposits recorded for the three months ended December 31, 2022.

Net loss was $3.7 million for the three months ended December 31, 2022, compared to $5.5 million for the same period in 2021.

Cash and cash equivalents, restricted cash and short-term bank deposits as of December 31, 2022 were $42.1 million as compared to $51.9 million as of December 31, 2021. On March 3, 2022, the Company consummated a registered direct offering for the sale of 1,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to an aggregate of 750,000 of the Company's ordinary shares. The registered direct offering resulted in gross proceeds to the Company of $10.0 million or approximately $8.9 million net of offering expenses.

The number of outstanding ordinary shares as of December 31, 2022 was 5,844,463.

Financial Results for the Twelve Months Ended December 31, 2022

Research and development expenses, net, were approximately $14.3 million for the twelve months ended December 31, 2022, compared to $12.3 million for the same period in 2021. The increase in research and development expenses, net between 2022 and 2021 was primarily due to (i) an increase of approximately $0.8 million in salary and related expense, mainly as a result of an expansion in head count that was offset in part by a reduction in bonuses expense in 2022 and by exchange rate fluctuations, (ii) an increase of approximately $0.6 million in subcontractors and consultants, including regulatory consultants, (iii) an increase of approximately $0.2 million in share-based compensation, (iv) an increase of approximately $0.8 million in other research and development expenses, including clinical study expenses, and (iv) a $0.2 million decrease in the participation of the Israel Innovation Authority in research and development expenses. The increase in research and development expenses, net between 2022 and 2021, was offset in part by a $0.8 million decrease in material expenses.

General and administrative expenses were approximately $5.8 million for the twelve months ended December 31, 2022, compared to approximately $5.0 million for the same period in 2021. The increase in general and administrative expenses is primarily due to (i) a $0.4 million increase in professional services expenses, (ii) a $0.2 million increase in share-based compensation expenses, and (iii) a $0.4 million increase in other general expenses, mainly associated with directors' and officers' liability insurance, offset in part by a $0.3 million decrease in salaries and related expenses, mainly due to a reduction in bonuses expense in 2022.

Operating loss was $20.0 million for the twelve months ended December 31, 2022, compared to $17.3 million for the same period in 2021.

Finance income, net, was approximately $926,000 for the twelve months ended December 31, 2021, compared to approximately $119,000 for the same period in 2021. The change in our finance income, net is primarily due to an increase of $946,000 of interest income on short-term deposits recorded for the year ended December 31, 2022, as compared to the year ended December 31, 2021, offset in part by a $173,000 decrease in fair value of derivatives recorded for the year ended December 31, 2022, as compared to the year ended December 31, 2021.

Net loss was approximately $19.1 million for the twelve months ended December 31, 2022, compared to approximately $17.2 million for the same period in 2021.

Net cash used in operating activities was $18.7 million for the twelve months ended December 31, 2022, compared to $16.3 million for the same period in 2021.

A copy of the Company's annual report on Form 20-F for the year ended December 31, 2022 has been filed with the U.S. Securities and Exchange Commission at www.sec.gov and posted on the Company's investor relations website at http://ir.check-cap.com/home. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to Mira Rosenzweig, chief financial officer, at This email address is being protected from spambots. You need JavaScript enabled to view it..

About Check-Cap
Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. The Company's disruptive capsule-based screening technology aims to help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. It requires no bowel preparation, allowing the patients to continue their daily routine with no interruption. C-Scan is not intended to replace colonoscopy. A positive C-Scan result should be followed by colonoscopy. C-Scan is an investigational device and is not available for sale in the United States. 

Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" about the Company's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts
Irina Koffler 
LifeSci Advisors, LLC 
646.970.4681
This email address is being protected from spambots. You need JavaScript enabled to view it.

Meirav Gomeh-Bauer
LifeSci Advisors, LLC 
+972(0)-54-476-4979
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Mónica Rouco Molina
Associate Director - Europe
LifeSci Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.